The Medical Letter on Drugs and Therapeutics
Apremilast (Otezla) for Psoriatic Arthritis
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

Apremilast (Otezla – Celgene), an oral phosphodiesterase type-4 (PDE4) inhibitor, has been approved by the FDA for treatment of active psoriatic arthritis in adults. It is the first PDE4 inhibitor to be approved for this indication.

STANDARD TREATMENT — Up to 40% of patients with psoriasis develop psoriatic arthritis.1 Nonsteroidal anti-inflammatory drugs (NSAIDs) may be tried first for treatment of mild disease. The disease-modifying antirheumatic drug (DMARD) methotrexate is generally used for treatment of moderate to severe disease. If there is minimal improvement after 12-16 weeks of methotrexate treatment, a tumor necrosis factor (TNF) inhibitor is often added or substituted.2 Ustekinumab (Stelara), a human interleukin-12 and -23 antagonist, has also been approved by the FDA for treatment of active psoriatic arthritis; how ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Apremilast (Otezla) for Psoriatic Arthritis
Article code: 1443a
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian